{"To": [0], "provide": [1, 268], "an": [2], "update": [3, 61], "of": [4, 53, 73, 77, 89, 93, 108, 173, 205, 214, 256, 260, 273], "the": [5, 19, 24, 59, 94, 226, 237, 271], "European": [6], "League": [7], "Against": [8], "Rheumatism": [9], "(EULAR)": [10], "rheumatoid": [11], "arthritis": [12], "(RA)": [13], "management": [14, 272], "recommendations": [15, 36, 105, 267], "to": [16, 185, 190, 195, 225, 277], "account": [17], "for": [18], "most": [20], "recent": [21], "developments": [22], "in": [23], "field.An": [25], "international": [26], "task": [27, 96], "force": [28, 97], "considered": [29], "new": [30], "evidence": [31, 74, 257], "supporting": [32], "or": [33, 212, 219, 236, 240], "contradicting": [34], "previous": [35], "and": [37, 40, 51, 75, 81, 103, 136, 140, 162, 171, 181, 258, 281], "novel": [38], "therapies": [39], "strategic": [41], "insights": [42], "based": [43], "on": [44, 49, 86, 99, 155, 164, 270], "two": [45, 215], "systematic": [46], "literature": [47], "searches": [48], "efficacy": [50], "safety": [52], "disease-modifying": [54], "antirheumatic": [55], "drugs": [56], "(DMARDs)": [57], "since": [58], "last": [60], "(2016)": [62], "until": [63], "2019.": [64], "A": [65], "predefined": [66], "voting": [67], "process": [68], "was": [69], "applied,": [70], "current": [71], "levels": [72, 259], "strengths": [76], "recommendation": [78], "were": [79, 262], "assigned": [80], "participants": [82], "ultimately": [83], "voted": [84], "independently": [85], "their": [87], "level": [88], "agreement": [90, 261], "with": [91, 275], "each": [92], "items.The": [95], "agreed": [98], "5": [100], "overarching": [101], "principles": [102], "12": [104], "concerning": [106], "use": [107], "conventional": [109], "synthetic": [110, 142], "(cs)": [111], "DMARDs": [112, 121, 144, 247], "(methotrexate": [113], "(MTX),": [114], "leflunomide,": [115], "sulfasalazine);": [116], "glucocorticoids": [117], "(GCs);": [118], "biological": [119], "(b)": [120], "(tumour": [122], "necrosis": [123], "factor": [124], "inhibitors": [125, 149], "(adalimumab,": [126], "certolizumab": [127], "pegol,": [128], "etanercept,": [129], "golimumab,": [130], "infliximab),": [131], "abatacept,": [132], "rituximab,": [133], "tocilizumab,": [134], "sarilumab": [135], "biosimilar": [137], "(bs)": [138], "DMARDs)": [139], "targeted": [141], "(ts)": [143], "(the": [145], "Janus": [146], "kinase": [147], "(JAK)": [148], "tofacitinib,": [150], "baricitinib,": [151], "filgotinib,": [152], "upadacitinib).": [153], "Guidance": [154], "monotherapy,": [156], "combination": [157], "therapy,": [158], "treatment": [159], "strategies": [160], "(treat-to-target)": [161], "tapering": [163], "sustained": [165, 245], "clinical": [166], "remission": [167], "is": [168, 198, 242], "provided.": [169], "Cost": [170], "sequencing": [172], "b/tsDMARDs": [174], "are": [175], "addressed.": [176], "Initially,": [177], "MTX": [178], "plus": [179], "GCs": [180], "upon": [182], "insufficient": [183], "response": [184], "this": [186, 229], "therapy": [187], "within": [188], "3": [189], "6": [191], "months,": [192], "stratification": [193], "according": [194], "risk": [196], "factors": [197, 203], "recommended.": [199, 243], "With": [200], "poor": [201], "prognostic": [202], "(presence": [204], "autoantibodies,": [206], "high": [207], "disease": [208], "activity,": [209], "early": [210], "erosions": [211], "failure": [213], "csDMARDs),": [216], "any": [217, 231], "bDMARD": [218, 233], "JAK": [220], "inhibitor": [221], "should": [222], "be": [223, 249, 253], "added": [224], "csDMARD.": [227], "If": [228], "fails,": [230], "other": [232], "(from": [234], "another": [235], "same": [238], "class)": [239], "tsDMARD": [241], "On": [244], "remission,": [246], "may": [248], "tapered,": [250], "but": [251], "not": [252], "stopped.": [254], "Levels": [255], "mostly": [263], "high.These": [264], "updated": [265], "EULAR": [266], "consensus": [269], "RA": [274], "respect": [276], "benefit,": [278], "safety,": [279], "preferences": [280], "cost.": [282]}